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of the Bing-Neel syndrome since it had been documented for at least 5 years before diagnosis of macroglobulinaemia, although a previous case has been reported where neuropathy was present four years before macroglobulinaemia was diagnosed". It remains possible that it was secondary to longstanding alcohol abuse.
This patient's presentation of macroglobulinaemia with a single manifestation of basal ganglia disease is rare. We would suggest that it is worthwhile checking serum proteins in any middle-aged or elderly patient with unusual central nervous system signs and/or peripheral neuropathy when other causes have been excluded.
The anxiogenic jungle of modern civilization produces many varied and persisting stresses that create anxiety in many people. Should we use anxiolytic drugs to help them survive when their coping mechanisms fail? Or should we use a non-drug approach? The meeting addressed itself to these problems and a number of distinguished speakers covered differing aspects of the subject.
The diverse uses ofbenzodiazepines(BDZs) in clinical practice were considered by Michael Trimble (National Hospital for Nervous Diseases) who emphasized that any equation of BDZs with anxiety is misleading since these drugs have myorelaxant, anticonvulsant, sedative and amnesic properties, all of which have been used for their clinical effects. For example, the 1,5 BDZ clobazam is a broad-spectrum anticonvulsant used as adjunctive therapy in epilepsy; whilst spasticity and dystonic syndromes variably respond to the muscle relaxant properties ofthe BDZs. They have been used as amnesic agents prior to surgery and also have potential use in affective disorders such as, for example, mania. BDZswith short elimination half-lives can be recommended as hypnotics and also in severe anxiety unresponsive to behavioural treatments and in trauma-induced acute anxiety.
Dr Peter Tyrer (St Charles Hospital, London) emphasized that BDZ use is still over-shadowed by the risks of dependence and this dwarfs all other problems posed by these drugs. Recent research has been directed towards better identification of the factors predisposing to dependence: dosage, duration 2 Waldenstrom J. Incipient myelomatosis, or "essential" fib- Neurology 1978; 30:536-8 (Accepted 16 February 1989) of treatment, type of BDZ and personality status of the consumers. Against the dangers of dependence must be balanced the relative merits of long-term use in: panic disorder, recurring neurotic symptomatology and intermittent alcohol abuse. Other problems are the type and extent of cognitive and sensorimotor impairment, lack of efficacyafter repeated dosage and illegal use of BDZs.
Many of the problems with the BDZs are related to the pharmacokinetics of the different compounds and Robin Braithwaite (Regional Laboratory for Toxicology, Birmingham) described the development and introduction of new more potent BDZ hypnotics with a rapid onset of action, fast rate of elimination and minimal residual effects. Simple differences in the plasma drug concentration-time curve do not fully explain differences in the duration of clinical action and the rate of passage to and from the CSF and brain, together with interaction with BDZreceptor sites, are important factors. The pharmacokinetic properties of some BDZs are more likely to create dependence problems whereas others lend themselves to the management of BDZ withdrawal.
Cognitive impairment with the BDZswas considered by Ian Hindmarch (Department of Psychology, University of Leeds) who suggested that the effects of a tranquillizer might be likened to being 'wrapped in emotional cotton wool'. However, not all compounds are the same, as illustrated by a trial of clobazam compared with lorazepam; the anxiolytic effects were the same but short-term memory was impaired by the latter but not by the former. In another study comparing clobazam with clorazepate, there was a return of anxiety after stopping the clorazepate but relief of anxiety was maintained after stopping clobazam. In a further study of clobazam against bromazepam, the latter was ineffective in relieving anxiety.
On cognitive driving tests clobazam showed no adverse effects whereas lorazepam caused considerable impairment. Buspirone in a dose of 5 mg does not impair reaction time tests but there is some initial impairment on increasing the dose to 10 mg. Buspirone also impairs memory whereas clobazam does not. Alpidem also produces a transient effect but only with 100 mg, there being no effect with 25 and 50 mg. Both placebo and alcohol in small doses produced more sedation than alpidem; whilst lorazepam was considerably more sedative. There was no potentiation between alpidem and alcohol although there was considerable interaction with lorazepam.
Cornelius Katona <Whittington Hospital, London) considered the particular problems of using BDZ in the elderly. In a comparison between nitrazepam and temazepam, the former produced cognitive impairment on the first day, whereas the latter did not; but by 7 days both caused this adverse effect. It is important to appreciate that 13% of the elderly have alcohol problems and it is this group that is most likely to suffer from insomnia. Triazolam can cause an acute withdrawal syndrome with persecutory delusions and so the decision to use these drugs in the elderly is even more critical than in younger age groups.
The problem of adverse drug reactions (ADRs) (as opposed to long-term problems) was surveyed by Susan Wood (Principal Medical Officer, Committee on Safety of Medicines), who emphasized that premarketing clinical trials on small numbers of patients can only lead to the detection of ADRs which occur at a relatively high frequency of 0.2-1 %. Post-marketing surveillance is therefore crucial to detect less common ADRs and in the UK, a number of schemes exist for this purpose. Information from many of these sources has shown that BDZs are associated with a variety of ADRs, the majority being related to effects on the central nervous system (CNS). Some are extensions of dose-related pharmacological effects, others are idiosyncratic and yet others due to withdrawal, development of tolerance and drug dependence. It has taken some time to assess the problem accurately, in part because it may be difficult to distinguish withdrawal effects from the symptoms of the original illness. The advice of the Committee on Safety on Medicines is therefore that the BDZs should be reserved for the short-term relief(2-4 weeks) of severe, disabling anxiety and/or insomnia.
The new alternatives to the BDZs were considered by David Wheatley (Maudsley Hospital, London); drugs that have been developed to produce equivalent tranquillization with minimal side-effects and lack of dependence potential. Buspirone was the first to be introduced to clinical practice in the UK and in a trial against placebo and diazepam, although there was a well marked placebo effect in the first 1 or 2 weeks, this was lost by the third week. On the other hand, diazepam produced a progressive and highly significant relief of anxiety throughout the trial whereas the onset of effect with buspirone was Journal of the Royal Society of Medicine Volume 83 April 1990 275 much slower. Alpidem and suriclone are two further compounds under trial, but in a comparison between alpidem, placebo and oxazepam, equivalent anxiolytic effects were recorded, with no significant differences between them. Insomnia is an almost invariable accompaniment of anxiety and zopiclone and zolpidem are short-acting hypnotics, the effects of which have been demonstrated in two studies undertaken by the Psychopharmacology Research Group, comparing zopiclone to temazepam and zolpidem to placebo respectively. Both were found to be effective hypnotics but longer-term studies will be necessary before they can be declared free of the disadvantages of the BDZs which they are aimed to replace. The simplistic 'fight or flight' reaction is inappropriate to cope with the anxiogenic jungle of civilization and, since we have not yet developed the means of self-tranquillization, it is appropriate that development of new anxiolytic drugs should continue in order to provide safer and more effective alternatives.
Richard Pearson (St Bartholomew's Hospital, London) considered an alternative to tranquillization with drugs, namely the use of adrenergic betablockers in anxiety. This was a response to the very real needs caused by disabling symptoms of performance-related anxiety in instrumental musicians. Prior to the introduction of these drugs for performance-related anxiety, many musicians took BDZ or alcohol, often with career-ending results. In order to assess the effects of beta-receptor blocking drugs on performance in instrumental musicians, a double-blind placebo-controlled crossover study was completed in string players at the Wigmore Hall which assessed the effects of 40 mg oxprenolol. This confirmed an improvement in various aspects of performance as judged both by the musicians and experienced competition judges. Since that study, the use of these drugs has extended. A recent survey showed that 21% of over 2000 instrumental musicians had performance-related anxiety and in these the problem was severe in 38%. Of the whole group 27% used beta-blocking drugs to combat their symptoms. Of the musicians using betareceptor blocking drugs, 19% took them on a prescription every day, 11% took them on prescription occasionally, while 70% took them occasionally not on prescription. These drugs should be used with care in patients in whom asthma or Raynaud's phenomenon have been excluded. A trial run should be given outside the performance situation and careful advice given on dosage. Their use in singers is contra-indicated since they cause drying of the mucous membranes and reduce the 'support' for the voice.
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